🔎 Trials Near Me

홈 › 비소세포폐암 › 오하이오

오하이오의 비소세포폐암 임상 시험

비소세포폐암 관련 연구 120개가 오하이오 내 여러 지역에서 참여자를 모집하고 있습니다.

오하이오의 도시

공식 연구 텍스트(영어)

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • University of Cincinnati Cancer Center, Cincinnati
  • The Ohio State University, Columbus
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06765109

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

  • ALX Center 10, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07085091

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  • Local Institution - 0383, Cincinnati
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07361510

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Cleveland Clinic Akron General, Akron
  • Strecker Cancer Center-Belpre, Belpre
  • Aultman Health Foundation, Canton
  • 외 33개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT04267848

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

  • Site 06, Maumee
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07814248

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Akron General Medical Center, Akron
  • The Christ Hospital, Cincinnati
  • University Hospitals Cleveland Medical Center, Cleveland
  • 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07361497

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • ProMedica Flower Hospital, Sylvania
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07388524

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  • The Mark H Zangmeister Center /ID# 272502, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • TriHealth Cancer & Blood Institute Research, Cincinnati
  • Taylor Cancer Research Center, Maumee
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06881784

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Aultman Health Foundation, Canton
  • Miami Valley Hospital South, Centerville
  • Ohio State University Comprehensive Cancer Center, Columbus
  • 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06498635

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • University of Cincinnati Medical Center ( Site 0119), Cincinnati
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06623422

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
  • Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
  • Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
  • 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07144280

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Aultman Hospital, Canton
  • Aultman Medical Group Hematology and Oncology, Canton
  • Oncology Hematology Care Clinical Trials, Cincinnati
  • 외 7개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07222566

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
  • University Hospitals Cleveland Medical Center, Cleveland
  • University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
  • 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06758401

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Canton
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06868277

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Dayton Physician's Network, Dayton
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Cincinnati Veterans Affairs Medical Center, Cincinnati
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06667076

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • The Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04981119

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  • University Hospitals Cleveland Medical Center, Cleveland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06667908

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Aultman Hospital, Canton
  • Miami Valley Hospital South, Centerville
  • Fairview Hospital, Cleveland
  • 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06890598

Pan-tumor MRD Study

  • Gabrail Cancer Center, Canton
  • Taylor Cancer Research Center, Maumee
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06605404

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Cleveland
피험자 모집 중2상
18세 ~ 95세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05061550

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Cincinnati
  • Research Site, Maumee
  • Research Site, Toledo
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06357533

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • Cleveland Clinic, Cleveland
  • Local Institution - 0102, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06618287

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Local Institution - 0486, Centerville
  • University of Cincinnati Medical Center, Cincinnati
  • Local Institution - 0519, Elyria
  • 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06561386

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • University Hospitals Cleveland Medical Center, Cleveland
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07100080

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Gabrail Cancer Center Research, Canton
  • The Christ Hospital Cancer Center, Cincinnati
  • University of Cincinnati Medical Center, Cincinnati
  • 외 5개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06712316

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07104630

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • Mercy Health - Perrysburg Cancer Center /ID# 270536, Perrysburg
  • Genesis Healthcare System /ID# 273361, Zanesville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06568939

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

  • Ohio State University, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT06529822

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Cincinnati
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Sites, Cincinnati
  • Clinical Study Site, Cleveland
  • Clinical Study Sites, Columbus
  • 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06767514

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  • Gabrail Cancer Center, Canton
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06855771

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Cleveland Clinic, Cleveland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT05786924

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

  • Gabrail Cancer Center Research, Canton
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT04486833

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Local Institution - 007-893-B, Cincinnati
  • USOR - Oncology Hematology Care - Blue Ash, Cincinnati
  • Local Institution - 007-893-C, Cincinnati
  • 외 5개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT04613596

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04585750

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  • Gabrail Cancer Center, Canton
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT06899126

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

  • Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04780568

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.